Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids. 2018

Nilufar Mossaheb, and Konstantinos Papageorgiou, and Miriam R Schäfer, and Jana Becker, and Monika Schloegelhofer, and G Paul Amminger
Department of Psychiatry and Psychotherapy, Clinical Division of Social Psychiatry, Medical University Vienna, Vienna, Austria.

The aim of this analysis was to assess changes in lipid parameters, specifically in triglyceride (TG) levels, in a population at ultra-high risk (UHR) for psychosis treated with ω-3 polyunsaturated fatty acids (PUFAs) versus placebo. Data were derived from a randomized, double-blind, placebo-controlled trial conducted at an early psychosis unit. Eighty-one individuals, aged 13-25 years, at UHR for psychosis participated in a 12-week intervention trial of 1.2 g/day of ω-3 PUFAs (n = 41) versus placebo (n = 40). Lipid and C-reactive protein levels were collected at baseline and after 12 weeks. Between-group comparisons showed no significant difference in TG levels after the intervention. However, in individuals with baseline TG levels above 150 mg dL-1 there was a significant mean TG reduction of 67.29 (SD 42.54; P = 0.006) in the ω-3 group (n = 7). In this sample of UHR individuals, a 12-week intervention with ω-3 PUFAs was effective in reducing previously elevated TG levels. This might introduce the possibility of altering the lipid profile and thus the risk of cardiovascular morbidity of UHR individuals.

UI MeSH Term Description Entries
D008297 Male Males
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014280 Triglycerides An ester formed from GLYCEROL and three fatty acid groups. Triacylglycerol,Triacylglycerols,Triglyceride
D015525 Fatty Acids, Omega-3 A group of unsaturated fatty acids occurring mainly in fish oils, with three double bonds at particular positions in the hydrocarbon chain. N-3 Fatty Acid,Omega-3 Fatty Acid,Omega-3 Fatty Acids,n-3 Fatty Acids,n-3 Oil,n3 Oil,Omega 3 Fatty Acids,n-3 Oils,n-3 PUFA,n-3 Polyunsaturated Fatty Acid,n3 Fatty Acid,n3 Oils,n3 PUFA,n3 Polyunsaturated Fatty Acid,Acid, N-3 Fatty,Acid, Omega-3 Fatty,Fatty Acid, N-3,Fatty Acid, Omega-3,Fatty Acid, n3,N 3 Fatty Acid,Oil, n-3,Oil, n3,Omega 3 Fatty Acid,PUFA, n-3,PUFA, n3,n 3 Fatty Acids,n 3 Oil,n 3 Oils,n 3 PUFA,n 3 Polyunsaturated Fatty Acid

Related Publications

Nilufar Mossaheb, and Konstantinos Papageorgiou, and Miriam R Schäfer, and Jana Becker, and Monika Schloegelhofer, and G Paul Amminger
August 2021, Early intervention in psychiatry,
Nilufar Mossaheb, and Konstantinos Papageorgiou, and Miriam R Schäfer, and Jana Becker, and Monika Schloegelhofer, and G Paul Amminger
March 2014, Molecular psychiatry,
Nilufar Mossaheb, and Konstantinos Papageorgiou, and Miriam R Schäfer, and Jana Becker, and Monika Schloegelhofer, and G Paul Amminger
December 2020, Schizophrenia research,
Nilufar Mossaheb, and Konstantinos Papageorgiou, and Miriam R Schäfer, and Jana Becker, and Monika Schloegelhofer, and G Paul Amminger
January 2018, Brazilian dental journal,
Nilufar Mossaheb, and Konstantinos Papageorgiou, and Miriam R Schäfer, and Jana Becker, and Monika Schloegelhofer, and G Paul Amminger
January 2015, Translational psychiatry,
Nilufar Mossaheb, and Konstantinos Papageorgiou, and Miriam R Schäfer, and Jana Becker, and Monika Schloegelhofer, and G Paul Amminger
January 2022, Early intervention in psychiatry,
Nilufar Mossaheb, and Konstantinos Papageorgiou, and Miriam R Schäfer, and Jana Becker, and Monika Schloegelhofer, and G Paul Amminger
October 2012, Nature reviews. Cardiology,
Nilufar Mossaheb, and Konstantinos Papageorgiou, and Miriam R Schäfer, and Jana Becker, and Monika Schloegelhofer, and G Paul Amminger
September 2014, Schizophrenia research,
Nilufar Mossaheb, and Konstantinos Papageorgiou, and Miriam R Schäfer, and Jana Becker, and Monika Schloegelhofer, and G Paul Amminger
October 2017, Schizophrenia research,
Nilufar Mossaheb, and Konstantinos Papageorgiou, and Miriam R Schäfer, and Jana Becker, and Monika Schloegelhofer, and G Paul Amminger
February 2020, Biological psychiatry,
Copied contents to your clipboard!